|
시장보고서
상품코드
1869762
희소 세포 분리 시장 : 규모, 점유율과 동향 분석, 제품별, 세포 유형별, 기술별, 지역별, 부문 예측(2025-2033년)Rare Cell Isolation Market Size, Share & Trends Analysis Report By Product (Reagents & Kits, Instrument), By Cell Type (Circulating Tumor Cells, Stem Cells, Rare Immune Cells, Fetal Cells), By Technology, By Region, And Segment Forecasts, 2025 - 2033 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
희소 세포 분리 시장 요약
세계의 희소 세포 분리 시장 규모는 2024년에 20억 2,000만 달러로 평가되었고, 2033년까지 50억 9,000만 달러에 이를 것으로 예측됩니다.
2025년부터 2033년에 걸쳐 CAGR 10.85%로 성장할 전망입니다. 희소 세포 분리 시장은 생명 공학의 진보와 정밀의료에 대한 수요 증가를 배경으로 현저한 성장을 이루고 있습니다.
순환종양세포(CTCs), 줄기세포, 태아세포 등을 포함한 희소세포는 질병의 조기 발견, 치료 경과의 모니터링, 맞춤형 치료에 있어 매우 중요한 역할을 하고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 희소 세포 분리 시장의 변수, 동향, 범위
- 시장 계통 전망
- 상위 시장 전망
- 관련/부수 시장 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 희소 세포 분리 시장 분석 툴
- 업계 분석 - Porter's Five Forces 분석
- PESTEL 분석
제4장 희소 세포 분리 시장 : 제품의 추정·동향 분석
- 부문 대시보드
- 세계의 희소 세포 분리 시장에서의 제품의 변동 분석
- 희소 세포 분리 시장 규모와 동향 분석(제품별, 2021-2033년)
- 시약 및 키트
- 기기
제5장 희소 세포 분리 시장 : 세포 유형의 추정·동향 분석
- 부문 대시보드
- 희소 세포 분리 시장의 변동 분석
- 희소 세포 분리 시장 규모와 동향 분석(세포 유형별, 2021-2033년)
- 순환 종양 세포
- 줄기세포
- 태아세포
- 희귀 면역 세포
- 순환 내피 세포
- 기타 희귀 세포 유형
제6장 희소 세포 분리 시장 : 기술의 추정·동향 분석
- 부문 대시보드
- 희소 세포 분리 시장에서의 기술 변동 분석
- 희소 세포 분리 시장 규모와 동향 분석(기술별, 2021-2033년)
- 마이크로플루이딕스공학에 기초한 기술
- 형광 활성화 세포 선별
제7장 희소 세포 분리 시장 : 지역의 추정·동향 분석
- 지역별 시장 점유율 분석, 2024년 및 2033년
- 지역 시장 대시보드
- 시장 규모, 예측 동향 분석, 2021-2033년:
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
- 라틴아메리카
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트
제8장 경쟁 구도
- 기업/경쟁의 분류
- 전략 매핑
- 기업시장 포지셔닝 분석, 2024년
- 기업 프로파일
- Miltenyi Biotec
- Thermo Fisher Scientific, Inc.
- Danaher
- QIAGEN NV
- Bio-techne
- STEMCELL Technologies
- CELLENION
- RareCyte
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
Rare Cell Isolation Market Summary
The global rare cell isolation market size was valued at USD 2.02 billion in 2024 and is projected to reach USD 5.09 billion by 2033, growing at a CAGR of 10.85% from 2025 to 2033. The rare cell isolation market has been experiencing significant growth, driven by advancements in biotechnology and the increasing need for precision medicine.
Rare cells, which include circulating tumor cells (CTCs), stem cells, and fetal cells, play crucial roles in early disease detection, treatment monitoring, and personalized therapy.
Global Rare Cell Isolation Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rare cell isolation market report based on product, cell type, technology, and region:
- Products Outlook (Revenue, USD Million, 2021 - 2033)
- Reagent & Kits
- Instrument
- Cell Type Outlook (Revenue, USD Million, 2021 - 2033)
- Circulating Tumor Cells
- Stem Cells
- Fetal Cells
- Rare Immune Cells
- Circulating Endothelial Cells
- Other Rare Cell Types
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Magnetic Bead Separation
- Fluorescence-Activated Cell Sorting
- Microfluidics-based techniques
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Products Segment
- 1.2.2. Cell Type Segment
- 1.2.3. Technology Segment
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
Chapter 3. Rare cell isolation market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising prevalence of chronic and rare diseases
- 3.2.1.2. Technological advancement and innovation in cell isolation
- 3.2.2. Market restraint analysis
- 3.2.2.1. Strict regulations and compliances for cell separation
- 3.2.1. Market driver analysis
- 3.3. Rare Cell Isolation Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
Chapter 4. Rare Cell Isolation Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Rare Cell Isolation Market Products Movement Analysis
- 4.3. Global Rare Cell Isolation Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Reagent & Kits
- 4.4.1. Reagent & kits market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5. Instrument
- 4.5.1. Instrument market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Rare Cell Isolation Market: Cell Type Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Rare Cell Isolation Market Application Movement Analysis
- 5.3. Global Rare Cell Isolation Market Size & Trend Analysis, by cell type, 2021 to 2033 (USD Million)
- 5.4. Circulating Tumor Cells
- 5.4.1. Circulating tumor cells market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5. Stem Cells
- 5.5.1. Stem cells market estimates and forecasts 2021 to 2033 (USD Million)
- 5.6. Fetal Cells
- 5.6.1. Fetal cells market estimates and forecasts 2021 to 2033 (USD Million)
- 5.7. Rare Immune Cells
- 5.7.1. Rare immune cells market estimates and forecasts 2021 to 2033 (USD Million)
- 5.8. Circulating Endothelial Cells
- 5.8.1. Circulating endothelial cells market estimates and forecasts 2021 to 2033 (USD Million)
- 5.9. Other Rare Cell Types
- 5.9.1. Other rare cell types market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Rare cell isolation market: Technology Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Rare Cell Isolation Market Technology Movement Analysis
- 6.3. Global Rare Cell Isolation Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
- 6.4. Microfluidics-Based Techniques
- 6.4.1. Microfluidics-based techniques market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5. Fluorescence-Activated Cell Sorting
- 6.5.1. Fluorescence-activated cell sorting market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Rare cell isolation market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. U.S.
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Competitive scenario
- 7.4.1.3. Regulatory framework
- 7.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.2. Canada
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Competitive scenario
- 7.4.2.3. Regulatory framework
- 7.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.3. Mexico
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Competitive scenario
- 7.4.3.3. Regulatory framework
- 7.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.1. U.S.
- 7.5. Europe
- 7.5.1. UK
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Competitive scenario
- 7.5.1.3. Regulatory framework
- 7.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.2. Germany
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Competitive scenario
- 7.5.2.3. Regulatory framework
- 7.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.3. France
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Competitive scenario
- 7.5.3.3. Regulatory framework
- 7.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.4. Italy
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Competitive scenario
- 7.5.4.3. Regulatory framework
- 7.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.5. Spain
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Competitive scenario
- 7.5.5.3. Regulatory framework
- 7.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.6. Denmark
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Competitive scenario
- 7.5.6.3. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.7. Sweden
- 7.5.7.1. Key country dynamics
- 7.5.7.2. Competitive scenario
- 7.5.7.3. Regulatory framework
- 7.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.8. Norway
- 7.5.8.1. Key country dynamics
- 7.5.8.2. Competitive scenario
- 7.5.8.3. Regulatory framework
- 7.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.1. UK
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Competitive scenario
- 7.6.1.3. Regulatory framework
- 7.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.2. China
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Competitive scenario
- 7.6.2.3. Regulatory framework
- 7.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.3. India
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Competitive scenario
- 7.6.3.3. Regulatory framework
- 7.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.4. Australia
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Competitive scenario
- 7.6.4.3. Regulatory framework
- 7.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Competitive scenario
- 7.6.5.3. Regulatory framework
- 7.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.6. Thailand
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Competitive scenario
- 7.6.6.3. Regulatory framework
- 7.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.1. Japan
- 7.7. Latin America
- 7.7.1. Brazil
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Competitive scenario
- 7.7.1.3. Regulatory framework
- 7.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7.2. Argentina
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Competitive scenario
- 7.7.2.3. Regulatory framework
- 7.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7.1. Brazil
- 7.8. MEA
- 7.8.1. South Africa
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Competitive scenario
- 7.8.1.3. Regulatory framework
- 7.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.2. Saudi Arabia
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Competitive scenario
- 7.8.2.3. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.3. UAE
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Competitive scenario
- 7.8.3.3. Regulatory framework
- 7.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.4. Kuwait
- 7.8.4.1. Key country dynamics
- 7.8.4.2. Competitive scenario
- 7.8.4.3. Regulatory framework
- 7.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.1. South Africa
Chapter 8. Competitive Landscape
- 8.1. Company/Competition Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Position Analysis, 2024
- 8.4. Company Profiles/Listing
- 8.4.1. Miltenyi Biotec
- 8.4.1.1. Company overview
- 8.4.1.2. Financial performance
- 8.4.1.3. Product benchmarking
- 8.4.1.4. Strategic initiatives
- 8.4.2. Thermo Fisher Scientific, Inc.
- 8.4.2.1. Company overview
- 8.4.2.2. Financial performance
- 8.4.2.3. Product benchmarking
- 8.4.2.4. Strategic initiatives
- 8.4.3. Danaher
- 8.4.3.1. Company overview
- 8.4.3.2. Financial performance
- 8.4.3.3. Product benchmarking
- 8.4.3.4. Strategic initiatives
- 8.4.4. QIAGEN N.V.
- 8.4.4.1. Company overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Product benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. Bio-techne
- 8.4.5.1. Company overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Product benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. STEMCELL Technologies
- 8.4.6.1. Company overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Product benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. CELLENION
- 8.4.7.1. Company overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Product benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. RareCyte
- 8.4.8.1. Company overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Product benchmarking
- 8.4.8.4. Strategic initiatives
- 8.4.9. Illumina, Inc.
- 8.4.9.1. Company overview
- 8.4.9.2. Financial performance
- 8.4.9.3. Product benchmarking
- 8.4.9.4. Strategic initiatives
- 8.4.10. Bio-Rad Laboratories, Inc.
- 8.4.10.1. Company overview
- 8.4.10.2. Financial performance
- 8.4.10.3. Product benchmarking
- 8.4.10.4. Strategic initiatives
- 8.4.1. Miltenyi Biotec
샘플 요청 목록